Ethics and eplerenone

Journal of Medical Ethics

Volumn 39, Issue 2, 2013, Pages 110-114

  Gupta, Shruti ^a   Fugh Berman, Adriane J ^b   Scialli, Anthony ^c  

^a GEORGETOWN UNIVERSITY MEDICAL CENTER   (United States)

^b Department of Pharmacology and Physiology ^*  (United States)

^c Tetra Tech Sciences   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DRUG DERIVATIVE; EPLERENONE; MINERALOCORTICOID ANTAGONIST; PLACEBO; SPIRONOLACTONE;

ARTICLE; CLINICAL TRIAL (TOPIC); COST BENEFIT ANALYSIS; DRUG COST; ECONOMICS; EQUIPOISE; ETHICS; FOOD AND DRUG ADMINISTRATION; HEART FAILURE; HUMAN; PERSONNEL; PROFESSIONAL STANDARD; PUBLICATION; RESEARCH ETHICS; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME; UNITED STATES;

CLINICAL TRIALS AS TOPIC; COST-BENEFIT ANALYSIS; DRUG COSTS; ETHICS COMMITTEES, RESEARCH; ETHICS, RESEARCH; HEART FAILURE; HUMANS; MINERALOCORTICOID RECEPTOR ANTAGONISTS; PERIODICALS AS TOPIC; PLACEBOS; RESEARCH PERSONNEL; SEVERITY OF ILLNESS INDEX; SPIRONOLACTONE; THERAPEUTIC EQUIPOISE; TREATMENT OUTCOME; UNITED STATES; UNITED STATES FOOD AND DRUG ADMINISTRATION;

EID: 84873161859     PISSN: 03066800     EISSN: 14734257     Source Type: Journal    
DOI: 10.1136/medethics-2011-100258     Document Type: Article

References (31)

1. Miller FG, Joffe S. Equipoise and the dilemma of randomized clinical trials. N Engl J Med 2011;364:476-80.
2. Freedman B, Weijer C, Glass KC. Placebo orthodoxy in clinical research. I: Empirical and methodological myths. J Law Med Ethics 1996;24:243-51.
3. Freedman B, Glass KC, Weijer C. Placebo orthodoxy in clinical research. II: Ethical, legal, and regulatory myths. J Law Med Ethics 1996;24:252-9.
4. Spironolactone or Aldactone entered in Drugs at FDA, http://www.accessdata.fda. gov/scripts/cder/drugsatfda/index.cfm?fuseaction=Search.Label_ApprovalHistory# apphist (last accessed 19 Jan 2012).
5. Batterink J, Stabler SN, Tejani AM, et al. Spironolactone for hypertension. Cochrane Database Syst Rev 2010;(8):CD008169.
6. Marrs JC. Spironolactone management of resistant hypertension. Ann Pharmacother 2010;44:1762-9.
7. Soberman JE, Weber KT. Spironolactone in congestive heart failure. Curr Hypertens Rep 2000;2:451-6.
8. Schouten J, Michielsen PP. Treatment of cirrhotic ascites. Acta Gastroenterol Belg 2007;70:217-22.
9. Brown J, Farquhar C, Lee O, et al. Spironolactone versus placebo or in combination with steroids for hirsutism and/or acne. Cochrane Database Syst Rev 2009;(2): CD000194.
10. Rathnayake D, Sinclair R. Use of spironolactone in dermatology. Skinmed 2010; 8(6):328-32; quiz 333.
11. http://www.drugstore.com/spironolactone/aldactone/100mg-tablets/qxn00228267350 (last accessed 19 Jan 2012).
12. Eplerenone entered in Drugs at FDA, http://www.accessdata.fda.gov/scripts/cder/drugsatfda/index.cfm?fuseaction=Search.Label_ApprovalHistory (last accessed 19 Jan 2012).
13. http://www.drugstore.com/eplerenone/inspra/50mg-tablets/qxn59762172001 (last accessed 19 Jan 2012).
14. http://www.drugstore.com/inspra/50mg-tablets/qxn00025172001 (last accessed 19 Jan 2012).
15. The Rales Investigators. Effectiveness of spironolactone added to an angiotensin-converting enzyme inhibitor and a loop diuretic for severe chronic congestive heart failure (the Randomized Aldactone Evaluation Study (RALES)). Am J Cardiol 1996;78:902-7.
16. Pitt B, Zannad F, Remme WJ, et al. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. N Engl J Med 1999;341:709-17.
17. Pitt B, Remme W, Zannad F, et al. Eplerenone Post-Acute Myocardial Infarction Heart Failure Efficacy Survival Study Investigators. Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med 2003;348:1309-21.
18. Zannad F, McMurray JJ, Krum H, et al. Eplerenone in patients with systolic heart failure and mild symptoms. N Engl J Med 2011;364:11-21.
19. Armstrong PW. Aldosterone antagonists-last man standing? N Engl J Med 2011;364:79-80.
20. Ezekowitz JA, McAlister FA. Aldosterone blockade and left ventricular dysfunction: a systematic review of randomized clinical trials. Eur Heart J 2009;30:469-77.
21. Pitt B, Roniker B. Eplerenone, a novel selective aldosterone receptor antagonist (SARA): dose finding study in patients with heart failure. J Am Coll Cardiol 1999; 15(Suppl. 1):188A.
22. Parthasarathy HK, Ménard J, White WB, et al. A double-blind, randomized study comparing the antihypertensive effect of eplerenone and spironolactone in patients with hypertension and evidence of primary aldosteronism. J Hypertens 2011;29:980-90.
23. Inspra Drug Approval Package, http://www.accessdata.fda.gov/drugsatfda_docs/nda/ 2002/21-437_Inspra.cfm (last accessed 19 Jan 2012).
24. Emanuel EJ, Wendler D, Grady C. What makes clinical research ethical? JAMA 2000;283:2701-11.
25. Pharmaceutical Research and Manufacturers of America. Principles on Conduct of Clinical Trials. http://www.phrma.org/sites/default/files/105/ 042009_clinical_trial_principles_final.pdf (last accessed 19 Jan 2012).
26. Zannad F, McMurray JJ, Drexler H, et al. Rationale and design of the Eplerenone in Mild Patients Hospitalization And SurvIval Study in Heart Failure (EMPHASIS-HF). Eur J Heart Fail 2010;12:617-22.
27. New England Journal of Medicine. Sponsorship, authorship, and responsibility. http://www.nejm.org/author-center/doi/full/10.1056/NEJMed010093 (last accessed 19 Jan 2012).
28. Temple R, Ellenberg SS. Placebo-controlled trials and active-control trials in the evaluation of new treatments. Part 1: ethical and scientific issues. Ann Intern Med 2000;133:455-63.
29. Ellenberg SS, Temple R. Placebo-controlled trials and active-control trials in the evaluation of new treatments. Part 2: practical issues and specific cases. Ann Intern Med 2000;133:464-70.
30. Fugh-Berman A, Dodgson SJ. Ethical considerations of publication planning in the pharmaceutical industry. Open Med 2008;2:e121-4.
31. Fugh-Berman AJ. The haunting of medical journals: how ghostwriting sold "HRT". PLoS Med 2010;7(9):e1000335.